Nyxoah S.A. (NYXH): חובות לטווח קצר של החברה

Nyxoah S.A. (NYXH) creates advanced implants to combat apnea and snoring, benefiting from the lifelong management of its clients. The business relies on growing demand from Western ENT centers, supported by fresh clinical reports. The current individual short-term debt figure is 0.03. The share price history below illustrates the price action amid the expansion of high-tech systems in the US and Europe.

Nyxoah S.A. utilizes external board suppliers for the assembly of neurostimulators, which necessitates precise working capital management. The total amount of short-term liabilities maturing within one year reflects the issuer's current liquidity and solvency. This indicator aggregates all urgent debts, highlighting the risks of funding shortages for operational activities. A reduction in this burden confirms financial stability, yet excessive contraction could limit component procurement. By analyzing the dynamics of the current debt load, an investor assesses the reliability of the company's capital structure.